Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennifer Venhorst

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Frontiers in Pharmacology|October 14, 2024
Integrating text mining with network models for successful target identification: <i>in vitro</i> validation in MASH-induced liver fibrosisJennifer Venhorst, Roeland Hanemaaijer, Remon Dulos, et al.
Scientific Reports|October 7, 2024
Identifying patient subgroups in MASLD and MASH-associated fibrosis: molecular profiles and implications for drug developmentManuel A González Hernández, Lars Verschuren, Martien P M Caspers, et al.
European Journal of Medicinal Chemistry|September 2, 2011
Biophysical and physicochemical methods differentiate highly ligand-efficient human D-amino acid oxidase inhibitorsJos H M Lange, Jennifer Venhorst, Maria J P van Dongen, et al.
Bioorganic & Medicinal Chemistry Letters|February 16, 2016
Optimization of N'-(arylsulfonyl)pyrazoline-1-carboxamidines by exploiting a novel interaction site in the 5-HT6 antagonistic binding pocketArnold van Loevezijn, Jennifer Venhorst, Wouter I Iwema Bakker, et al.
Journal of Medicinal Chemistry|August 27, 2011
N'-(arylsulfonyl)pyrazoline-1-carboxamidines as novel, neutral 5-hydroxytryptamine 6 receptor (5-HT₆R) antagonists with unique structural featuresArnold van Loevezijn, Jennifer Venhorst, Wouter I Iwema Bakker, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Frontiers in Pharmacology|October 14, 2024
Integrating text mining with network models for successful target identification: <i>in vitro</i> validation in MASH-induced liver fibrosisJennifer Venhorst, Roeland Hanemaaijer, Remon Dulos, et al.
Scientific Reports|October 7, 2024
Identifying patient subgroups in MASLD and MASH-associated fibrosis: molecular profiles and implications for drug developmentManuel A González Hernández, Lars Verschuren, Martien P M Caspers, et al.
European Journal of Medicinal Chemistry|September 2, 2011
Biophysical and physicochemical methods differentiate highly ligand-efficient human D-amino acid oxidase inhibitorsJos H M Lange, Jennifer Venhorst, Maria J P van Dongen, et al.
Bioorganic & Medicinal Chemistry Letters|February 16, 2016
Optimization of N'-(arylsulfonyl)pyrazoline-1-carboxamidines by exploiting a novel interaction site in the 5-HT6 antagonistic binding pocketArnold van Loevezijn, Jennifer Venhorst, Wouter I Iwema Bakker, et al.
Journal of Medicinal Chemistry|August 27, 2011
N'-(arylsulfonyl)pyrazoline-1-carboxamidines as novel, neutral 5-hydroxytryptamine 6 receptor (5-HT₆R) antagonists with unique structural featuresArnold van Loevezijn, Jennifer Venhorst, Wouter I Iwema Bakker, et al.
Pageof 2